PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 13, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC PINK: MPSYY,
XETRA: MOR) will publish its first six months' 2017 results on August 3, 2017 at 7:00 am CEST.
At 2:00 pm CEST (1:00 pm BST, 8:00 am EDT), the Management Board of MorphoSys AG will host a public conference call and webcast
to present MorphoSys's Half-Year Report 2017 and provide further details on the Company's latest developments.
Dial-in numbers (listen only):
Germany: +49 89 2444 32975
United Kingdom: +44 20 3003 2666
USA: +1 202 204 1514
We request that you please dial in up to 10 minutes before the call to ensure a prompt start and a secure line.
The presentation slides and webcast link will be available at the Company's website at www.morphosys.com/conference-calls. A
slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.
About MorphoSys:
MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the
field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of
biopharmaceuticals in the biotechnology industry. Based on its proprietary technology platforms, MorphoSys, together with its
partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical
development. In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates,
mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new
drug candidates for pharmaceutical partners and participates from the programs' further development success, through success-based
payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about
MorphoSys, visit http://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R),
Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties.
Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is
concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz Head of Corporate Communications & IR
Jochen Orlowski Associate Director Corporate Communications & IR
Alexandra Goller Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404 investors@morphosys.com
SOURCE: MorphoSys AG via the EQS Newswire distribution service including Press Releases and Regulatory
Announcements
